Background: Infections caused by Acinetobacter baumannii are difficult to cure due to the acquisition of resistance by these bacteria and lead to an increase in the general costs of hospitalization. The aim of this study was to determine tigecycline susceptibility of Acinetobacter baumannii strains isolated from intensive care unit and non-intensive care unit patients with skin and soft tissue infections. Methods: MICs were tested by Etest among 70 Acinetobacter baumannii isolates. Results: The MIC range was from 0.5 to 8.0 mg L -1 . For ESBL-producing Acinetobacter baumannii, as well as for strains without carbapenemases, the highest MIC to tigecycline value was 8.0 mg L -1 . For AmpC-producing Acinetobacter baumannii, the highest MIC to tigecycline value was 6.0 mg L -1 and, for MBL-producing strains, 2.0 mg L -1 .
Infections caused by Acinetobacter baumannii (A. baumannii), a non-fermenting bacillus, represent 15 .3% of all Gram-negative bacterial infections in Poland [1] . This kind of infection is difficult to cure due to the acquisition of resistance by these bacteria, especially in intensive care units (ICUs). The development of bacterial resistance prolongs the time of treatment and raises mortality, and consequently, leads to an increase in the general costs of hospitalization [1, 2] . The application of tigecycline may be one of the therapeutic options available [3] .
Tigecycline is the first commercially available broad-spectrum glycylcycline-class anitbiotic (active against bacteria with extended-spectrum b-lactamase substrate, plasmidmediated AmpC b-lactamase and metallo-b-lactamase). The bacteriostatic effect is achieved by reversibly binding to the 30S ribosomal subunit. Glycylcyclines bind to ribosomes 5-fold more potently than tetracycline and minocycline, which explains the better efficacy of this drug [3−5] . Tigecycline was registered in the European Union in May 2006 for the treatment of complicated intra-abdominal infections (cIAIs) and complicated skin and skin structure infections (cSSSIs), except for diabetic foot infections in adults [3−5] .
METHODS
The study was approved by the local Bioethical Committee (No. KBET/19/B /2013).
BACTERIAL ISOLATES
The study involved 70 strains of A. baumannii isolated from patients hospitalized in intensive care units (ICUs) and other surgical (non-ICU) departments in specialist hospitals in the Cracow area in the period 2009-2013. The clinical materials were surgical wound exudates -54 samples; blood -4 samples; peritoneal fluid -7 samples, and surgical biopsy samples -5 samples. Only one isolate per patient was accepted into the study.
SPECIES IDENTIFICATION AND ANTIMICROBIAL SUSCEPTIBILITY TESTING
Species identification was carried out with API 20 NE strips (bioMérieux, Warsaw, Poland) according to manufacturer's instructions.
Susceptibility to tigecycline was evaluated by Etest (bioMérieux, Warsaw, Poland) according to manufacturer's instructions on freshly prepared Mueller Hinton II Agar (Becton Dickinson, Warsaw, Poland). The plates were inoculated with a 0.5 McF bacterial suspension. The culture plates were incubated in ambient air at 35 ± 1° C for 18-20 h. Escherichia coli ATCC 25922 and Klebsiella pneumoniae ATCC 700603 strains were used as quality control samples.
The results were expressed as MIC range, MIC 50 and MIC 90 values in mg L -1 units.
EVALUATION OF RESISTANCE MECHANISMS
The presence of ESBL and AmpC phenotypes in the examined isolates were identified by double-disk susceptibility test (DDST) with ceftazidime (Oxoid, England, distributed by Argenta, Poznań, Poland) and cefotaxime (Oxoid) as indicators, and amoxicillin (Oxoid) and clavulanic acid (Oxoid) as inhibitors of ESBL. The MBL mechanism of resistance was detected by DDST with an EDTA disk, a disk containing a metallo-β-lactamase inhibitor and disks of ceftazidime (Oxoid) and imipenem (Oxoid), in accordance with the recommendations of the Polish National Reference Center for Antimicrobial Susceptibility Affairs (KORLD) based on EUCAST guidelines [6] .
STATISTICAL ANALYSIS
Statistical analysis was performed using R Language and Environment for Statistical Computing software [7] . A P value of ≤0.05 was considered to be significant.
RESULTS
Tigecycline MICs for Acinetobacter ranged from 0.5 to 8.0 mg L -1 . For ESBL-producing A. baumannii and for strains without carbapenemases, the highest MIC to tigecycline value was 8.0 mg L -1 . For AmpC-producing A. baumannii, the highest MIC to tigecycline value was 6.0 mg L -1 , and for MBL-producing strains, 2.0 mg L -1 . Detailed results are shown in Tables 1 and 2 
DISCUSSION
Since EUCAST has not determined in vitro breakpoints for susceptibility to tigecycline in relation to A. baumannii, conclusions should not be formally drawn as regards its sensitivity. Therefore, we compared the obtained MIC values with the distribution given by EUCAST [8, 9] . All strains that had MIC values ≤ 1 mg L -1 were considered sensitive to tigecycline and all strains that had MIC ≥ 2 mg L -1 were deemed insensitive (resistant) [10] . EUCAST recognizes that all strains with MIC ≤ 1 mg L -1 do not have mutations that can lead to the acquisition of resistance (apart from a natural and known resistance characteristic for a given species -determined by the EUCAST ECOFF value is as 1 mg L -1 ). However, Piewngam and Kiratisin [11] suggest that the MIC breakpoint should be modified to S ≤ 0.5 and R > 2 mg L -1 . It has been pointed out that the determination of the antimicrobial activity of tigecycline might vary with the use of different methods, while the disk diffusion method is not reliable as regards the determination of susceptibility to tigecycline and gives lower susceptibility rates as compared to Etest or the broth microdilution method (BMD) [10, 12] . Zarkotou et al. [13] compared the broth microdilution method with VITEK2, Etest and MIC test strips. They found that Etest produced susceptibility results similar to those obtained with broth microdilution, while MIC values obtained by VITEK2 were higher than in the case of other tests. Moreover, a good concordance of the disk diffusion, Etest and BMD methods was found by Piewngam and Kiratisin [11] . On the other hand, there are some publications which present the opposite conclusions. Draghi et al. [12, 14] . As shown above, there is a great problem with obtaining reliable results of Acinetobacter susceptibility testing to tigecycline as there are no standardized guidelines, while the results from many studies have been inconclusive.
In our study, we used Etest because we believe that if this test is prepared with proper care on freshly prapared medium and a proper inoculum density, it produces reliable results when correlated with the microdilution method.
Tigecycline MICs for Acinetobacter varied from 0.5 to 8.0 mg L -1 in our study. Moreover, 7.1% of the tested isolates were characterized by MIC values lower than or equal to ECOFF values and for 90% of isolates the the MIC value was ≥ 2 mg L -1 (the MIC 50 and MIC 90 values were 3 and 6 mg L -1 , respectively). Similar results indicating the presence of Acinetobacter strains with high MIC values were obtained by Piewngam and Kiratisin in a study of 290 isolates including MDR (multidrug resistant) strains from different clinical specimens from patients hospitalized at the University Hospital in Bangkok (MIC range, MIC 50, and MIC 90 values were 0.5-8.0 mg L -1 , 2.0 mg L -1 , and 4.0 mg L -1 , respectively) [11] . Navon-Venezia et al. [15] reported high tigecycline [17] .
Treatment of complicated intra-abdominal and complicated skin and soft tissue infections may contribute to the emergence and selection of multidrug-resistant bacterial strains in health care centres [18] . Although antibiotic resistance occurs in various hospital wards and clinics, it is best documented in the ICU. In addition, there are indications that more resistant bacteria occur in these units than in other wards [19] . For most antimicrobial agents, resistance was considerably higher among A. baumannii isolates collected from patients in ICUs than in non-ICU wards [5, 17] . We found that A. baumannii strains isolated from ICU patients have significantly higher MIC values for tigecycline (MIC 50 = 3.0 mg L -1 , MIC 90 = 4.0 mg L -1 ) than Enterobacteriaceae strains isolated from the same wards (MIC 50 = 1.5 mg L -1 ; MIC 90 = 3.0 mg L -1 ; Wilcoxon test; P = 1.629e-09; W = 2495.5) (Data not shown). However, when we compared Acinetobacter strains isolated from ICU and non-ICU patients, we did not observe any differences (Wilcoxon test, P = 0.3508; W = 535.5; Fig. 2 , Table 2 ).
In our study, A. baumannii strains with a MDR phenotype producing ESBL and AmpC had MIC 50 = 4.0 mg L -1 and MIC 90 = 6.0 mg L -1 and non-MDR MIC 50 /MIC 90 = 3.0 mg L -1 . Moreover, we found that strains without any resistant mechanisms for other drugs are seen on the distribution curve as a separate population with MICs below ECOFF, while strains with one or more mechanisms comprise another population (Fig. 3) . That suggests that some of our strains, despite their nosocomial source, have wild type phenotypes. Eser et al. evaluated the MICs of MDR Acinetobacter and found that all strains had MICs lower than 2 µg mL -1 with MIC 90 = 1.5 µg mL -1 [19] . Morfin-Otero and Dowzicky (2012) found lower MIC values (MIC 90 = 2 mg L -1 ) in MDR strains than non-MDR strains (1 mg L -1 ) [17] . We checked whether isolates from sterile body sites (blood, peritoneal fluid, surgical biopsy samples) have a different susceptibility profile from strains from non-sterile body sites (wound exudates). Although we presumed that the former should display a sensitivity similar to the wild type, there was no difference observed between the strains (Wilcoxon test, p-value = 0.186; W = 523).
Our results suggest that the majority of A. baumannii strains isolated from ICU and non-ICU patients produce extended-spectrum beta-lactamases as ESBL or AmpC phenotype. Strains in our study were often collected from patients with chronic recurrent soft tissue and skin infections treated numerous times using various antimicrobial drugs, which favoured the selection of multi-resistant strains.
The majority of A. baumannii strains isolated from ICU and non-ICU patients demonstrated high values of MIC range, MIC 50 and MIC 90 to tigecycline. These data sug gest that tigecycline cannot be an effective therapeutic option for the treatment of serious infections caused by A. baumannii.
